Virtual Library
Start Your Search
Cláudia Freitas
Author of
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics (ID 227)
- Event: WCLC 2020
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P01.15 - Immune-Related Adverse Effects of Immunotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma (ID 3372)
00:00 - 00:00 | Presenting Author(s): Cláudia Freitas
- Abstract
Introduction
Immunotherapy is nowadays one of the most used treatments in oncology, although it is not free of adverse effects. In this study, we intended to analyse therapeutic response and immune-related adverse effects (irAEs) of immunotherapy in a sample of patients with non-small cell lung carcinoma (NSCLC) treated with pembrolizumab or nivolumab.
Methods
In this retrospective study, clinical data from patients with diagnose of metastasized NSCLC, treated with pembrolizumab or nivolumab, were collected between June 2015 and January 2020 at the Pulmonology Department of Centro Hospitalar e Universitário São João, Porto, Portugal.
Results
In a sample of 147 patients, 38 patients (25,9%) developed irAEs, the majority being grade 1 or 2 (n=30, 20,4%). The commonest events were colitis (n=9, 6,1%), skin rash (n=7, 4,8%) and hyperthyroidism (n=6, 4,1%).
PFS and OS were statistically higher in the group with irAEs compared to the group of patients without irAEs among patients treated in 1st line (PFS: 18,2 months (CI(95%):5,0-31,5) vs. 4,8 months (CI(95%):2,6-6,9); OS: 20,2 months (CI(95%):7,5-34,5) vs. 6,0 months (CI(95%):3,4-9,0)) and in 2nd line or higher (PFS: 14,1 months (CI(95%):10,1-18,4) vs. 5,9 months (CI(95%):4,3-7,6); OS: 18,3 months (CI(95%):14,1-22,4) vs. 8,6 months (CI(95%):6,8-10,6)), p<0,05.
Conclusion
In this sample of patients with NSCLC treated with PD-1 blockers, results suggest an association between the occurrence of irAEs and a better therapeutic response.